Mizuho initiates Regenxbio stock coverage with outperform rating
Mizuho has started covering Regenxbio Inc. (NASDAQ:RGNX) with an outperform rating. The rating comes with a price target of $22.00, indicating a substantial upside potential of nearly 196% from the current stock price of $7.43. The stock has fallen 48% year-to-date, making this a potential buying opportunity according to Mizuho.
The investment firm attributes this rating to Regenxbio's development of gene therapy-based candidates for diseases with significant unmet medical needs. Their model focuses on two key assets in Regenxbio's pipeline. The first, RGX-202, targets Duchenne muscular dystrophy and has already generated pivotal Phase 3 data. Regz-202 is scheduled for a U.S. regulatory filing in the first quarter of 2027.
The second asset, ABBV-RGX-314 or sura-vec, is in partnership with AbbVie Inc. and tackles wet age-related macular degeneration and diabetic retinopathy. Top-line Phase 3 data for this asset are expected this quarter.
Mizuho acknowledges that there are disagreements among investors regarding both assets and the potential of gene therapies in general. To support their assessment, Mizuho claims to have developed the most robust and comprehensive financial model on Regenxbio. According to InvestingPro, the stock currently appears undervalued.
Regenxbio Inc. has also reported significant recent developments. The U.S. Food and Drug Administration has placed a clinical hold on its investigational gene therapy RGX-121 for Mucopolysaccharidosis type II following asymptomatic spine MRI findings in five participants. This has led H.C. Wainwright to lower its price target for Regenxbio from $23 to $21, while maintaining a Buy rating.
Meanwhile, Regenxbio's Phase 2 ALTITUDE study on diabetic retinopathy has yielded promising three-year data, showing that 60% of patients experienced significant improvement without additional treatment. Both H.C. Wainwright and Stifel have reaffirmed Buy ratings for Regenxbio, with price targets of $21 and $42 respectively.
Adding to the insider confidence, Regenxbio's director, Gregory Austin Ciongoli, made substantial insider share purchases. He acquired over 102,000 shares across two days, at an average price of approximately $9.25 per share. These insider transactions further reinforce the optimism surrounding Regenxbio's ongoing clinical progress and leadership confidence.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.